EMA Authorised: Rivastigmine Sandoz (rivastigmine) — Sandoz GmbH

View source ↗

Summary

EMA authorised rivastigmine Sandoz for dementia indications, including Alzheimer disease and Parkinson disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia
• Parkinson Disease

Drugs mentioned

• Rivastigmine Sandoz (rivastigmine)

Snippet

Status: Authorised. Therapeutic area: Dementia;Alzheimer Disease;Parkinson Disease. MAH: Sandoz GmbH. Decision date: 19/08/2026